-
1 week ago | 
centerforbiosimilars.com | Skylar Jeremias
States with less restrictive biosimilar substitution laws were more likely to have higher uptake of an interchangeable insulin glargine biosimilar, underscoring the impact state regulations can have on biosimilar adoption, according to a recent study published in JAMA.1This study was conducted to explore whether state-level substitution laws impact the uptake of interchangeable biosimilars in the US.
-
1 week ago | 
centerforbiosimilars.com | Skylar Jeremias
During the first quarter of 2025, pharmaceutical companies have taken charge to strengthen their biosimilar portfolios, announcing new deals and partnerships that are sure to provide patients across the immunology and oncology fields greater access to life-changing biologics.
-
1 week ago | 
centerforbiosimilars.com | Skylar Jeremias
As chronic diseases continue to drive 90% of the nation’s $4.5 trillion in annual health care spending, expanding access to lower-cost biosimilars emerged as a critical solution in a recent congressional hearing on lowering health care costs and improving patient access.1 Lawmakers from the House Committee on Ways and Means and 4 expert witnesses highlighted the $23.6 billion in savings already generated by biosimilars since their introduction in 2015, while calling attention to the barriers...
-
1 week ago | 
ajmc.com | Skylar Jeremias |Julie Parsons
Spinal muscular atrophy (SMA) management continues to evolve, but significant unmet needs remain, particularly for patients aged 2 years and older who have not received early disease-modifying treatments.
-
2 weeks ago | 
ajmc.com | Skylar Jeremias
Innovative drug delivery systems are emerging as promising solutions to overcome the limitations of traditional formulations by enabling sustained and targeted drug release in the gastrointestinal (GI) tract, particularly for treating inflammatory bowel disease (IBD), according to a recent review.1The review, published in Frontiers in Bioscience-Landmark, was conducted to address the challenges of GI drug delivery, such as low pH, enzymatic degradation, and rapid transit.
-
2 weeks ago | 
centerforbiosimilars.com | Skylar Jeremias
Biocon Biologics expands its oncology biosimilar roster after gaining FDA approval for Jobevne (bevacizumab-nwgd), the sixth biosimilar referencing Avastin (bevacizumab).1,2 The new recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF) receptors is indicated for the treatment of colorectal cancer, non–small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer, ovarian, fallopian tube, and primary peritoneal cancers.1 "The U.S\ FDA...
-
2 weeks ago | 
centerforbiosimilars.com | Skylar Jeremias
Teva Pharmaceuticals and Samsung Bioepis have announced the US launch of Epysqli (eculizumab-aagh), a biosimilar to the blockbuster biologic Soliris (eculizumab), following FDA approval for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG) in anti-acetylcholine receptor (AchR) antibody–positive adult patients.1,2 Epysqli will be available at a 30% discount off the wholesale acquisition cost of...
-
2 weeks ago | 
ajmc.com | Skylar Jeremias
2025 is expected to bring a number of new traditional and specialty pharmaceuticals, including the first generic and biosimilar competitors for blockbuster brands and innovative therapies for cancer and neurological disorders, according to 2 presentations at the annual meeting of the Academy of Managed Care Pharmacy.1,2 Before getting into the generics and 505(b)(2) products coming down the pipeline, Leslie Fish, PharmD, RPh, senior vice president of pharmacy at IPD Analytics, provided a...
-
2 weeks ago | 
ipdanalytics.com | Skylar Jeremias
A surge of generics, biosimilars, and innovative therapies are expected in 2025, addressing conditions from cancer to chronic diseases, as outlined at the Academy of Managed Care Pharmacy annual meeting.
-
2 weeks ago | 
centerforbiosimilars.com | Skylar Jeremias
Early market entry, efficient manufacturing, and strong market share are make-or-break factors for biosimilar success, according to a recent study evaluating development opportunities.1The study, published in Biologics: Targets and Therapy, was conducted in response to the growing need for cost-effective health care solutions, particularly through the adoption of biosimilars. As patents expire on major biologics, biosimilars present an opportunity to reduce health care expenditures.
